Indication
Hearing Loss Ototoxic
1 clinical trial
1 product
Product
SENS-401Clinical trial
A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic DiseaseStatus: Recruiting, Estimated PCD: 2024-06-01